ETCTN Early Drug Development Opportunity Leadership program administrative supplement to Cancer Center Support Grant

ETCTN 早期药物开发机会领导计划对癌症中心支持补助金的行政补充

• 批准号: 10363981
• 负责人: GEROLD BEPLER
• 金额: $ 12.5万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10363981
• 关键词: Administrative Supplement; African American; Area; Basic Science; Biopsy; CD8-Positive T-Lymphocytes; Cancer Burden; Cancer Center Support Grant; Cancer Control; Cancer Hospital; Cancer Patient; Catchment Area; Cells; Censuses; Cities; Clinic; Clinical Research; Clinical Trials; Compassion; Comprehensive Cancer Center; County; Education; Failure; Grant; Healthcare; Home; Household; Income; Institutes; Intervention; Leadership; Location; Malignant Neoplasms; Measures; Medically Underserved Area; Michigan; Minority; Minority Groups; Mission; Molecular; Molecular Profiling; Myeloid-derived suppressor cells; Neuroendocrine Carcinoma; Nivolumab; Parents; Patient Care; Patients; Physicians; Population; Population Research; Population Study; Poverty; Prior Therapy; Progression-Free Survivals; Quality of Care; Research; Research Institute; Resource Sharing; Resources; Safety; Therapeutic; Therapeutic Studies; Translational Research; Treatment Protocols; Treatment outcome; Tumor Biology; Tumor-associated macrophages; Tumor-infiltrating immune cells; U-Series Cooperative Agreements; United States Health Resources and Services Administration; United States National Institutes of Health; Universities; anticancer research; base; cancer care; disorder control; drug development; exome sequencing; ipilimumab; member; metropolitan; molecular imaging; neoplastic cell; neuroendocrine differentiation; operation; programmed cell death ligand 1; programs; response; social disparities; suburb; success; transcriptome sequencing; tumor; tumor microenvironment

This application is being submitted in response to the EDDOP Leadership Program via the mechanism PA-20- 272, “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).” The Karmanos Cancer Institute (KCI), founded in 1943, is a not-for-profit, cancer-only research and patient care organization in partnership with Wayne State University (WSU) in Michigan. The designation by the NCI as a Comprehensive Cancer Center was achieved in 1978. KCI operates its wholly-owned, free-standing, cancer hospital and ambulatory clinics (KCC) in Detroit and in Farmington Hills, a suburban location. As a member of McLaren Health Care (MHC), a not-for profit health care corporation, KCI is also responsible for cancer research, quality of care, and cancer care operations in all facilities owned and operated by MHC. Our catchment area covers 46 of Michigan's 83 counties with a population of 6.7 million people. This catchment area is home to 95% of our patients, and KCI sees one-third of all new cancer patients in the catchment area. The Southeast region of our catchment area includes the metropolitan Detroit, defined as a tri-county area (Wayne, Oakland, Macomb) and home to 3.86 million residents. The city of Detroit is the largest city in the state (672,000 residents). Detroit is a resource-challenged area, with a median household income of $27,838 and 37.9% of residents living below poverty level, compared to 16.7% in the state of Michigan. The majority of census tracts in the city of Detroit are medically underserved areas based on HRSA definitions. About 79% of Detroit residents identify as African American, a group that disproportionately carries KCI catchment area's cancer burden. In 2018, KCI physicians saw approximately 12,000 new cancer patients (including approximately 8,000 analytic cases), with approximately 15% representing minority groups. The annual number of new cancer cases in these 46 counties is approximately 39,000 and has not changed significantly since 2014. In FY19, our minority accrual to interventional treatment protocols was 24.2%. We have a long standing scientific and patient care commitment to the African American population of southeastern Michigan, as exemplified in the broad array of studies focused on molecular, therapeutic, and social disparities. This application profiles the strengths and successes of our four scientific Programs, Tumor Biology and Microenvironment (TBM, 01), Molecular Imaging (MI, 02), Molecular Therapeutics (MT, 03), and Population Studies and Disparities Research (PSDR, 04). The research efforts of these Programs is supported by nine Shared Resources (Cores), including one developing Core.

该申请是通过机制PA-20--响应EDDOP领导计划提交的 272，“现有NIH赠款和合作协议的行政补品（父级管理员协议 临床试验可选）。” Karmanos癌症研究所（KCI）成立于1943年，是一家非营利性，仅癌症的研究和患者 与密歇根州韦恩州立大学（WSU）合作的护理组织。 NCI的设计 作为一个综合的癌症中心，1978年实现了其全资，独立的， 底特律的癌症医院和门诊诊所（KCC）以及郊区的法明顿山。作为 KCI的非利润医疗保健公司McLaren Health Care（MHC）也负责 由MHC拥有和运营的所有设施中的癌症研究，护理质量和癌症护理业务。我们的 集水区覆盖了密歇根州83个县的46个人口，有670万人。这个流域 我们有95％的患者的住所，KCI看到集水区所有新癌症患者中有三分之一。 我们集水区的东南地区包括底特律大都会，定义为三县地区 （韦恩，奥克兰，麦克姆），拥有386万居民的所在地。底特律市是 州（672,000名居民）。底特律是一个资源挑战的地区，家庭收入中位数为27,838美元 和37.9％的居民生活在贫困水平以下，而密歇根州为16.7％。大多数 根据HRSA的定义，底特律市的人口普查区是医疗服务不足的地区。约有79％ 底特律居民被认为是非裔美国人，该组织不成比例地携带KCI集水区 癌症伯恩。 2018年，KCI医师看到了大约12,000名新癌症患者（包括 大约8,000例分析案例），约有15％代表少数群体。一年一度 这46个县的新癌症病例的数量约为39,000，尚未发生重大变化 自2014年以来，在2019财年，我们对介入治疗方案的少数族裔为24.2％。我们有很长的 对密歇根州东南部非裔美国人人口的科学和患者护理承诺， 如在广泛的研究中所举例说明的那样，集中于分子，治疗和社会差异。这 应用程序介绍了我们四个科学计划，肿瘤生物学和 微环境（TBM，01），分子成像（MI，02），分子疗法（MT，03）和种群 研究与差异研究（PSDR，04）。这些计划的研究工作得到了九个 共享资源（核心），包括一个正在发展的核心。